By Dean Seal
CNS Pharmaceuticals said its Berubicin treatment for an aggressive and usually fatal brain cancer didn't show a statistically significant difference in overall survival during a clinical trial, leading to a selloff of its shares.
The biopharmaceutical company said Tuesday that superiority in overall survival had been the primary endpoint of the trial for Berubicin, though the treatment still shows a favorable safety profile. An analysis of the trial's outcomes is still ongoing, CNS said.
Shares fell 55% to $1.52 in premarket trading.
The trial was comparing Berubicin to Lomustine, which is the current standard of care in recurrent or progressive Glioblastoma Multiforme.
CNS said the trial data shows overall survival is comparable between the two treatments, including for patients with the most unfavorable tumor markers.
"We are awaiting long-term follow-up of patients still alive as well as those still on trial, and will evaluate our substantial clinical dataset to obtain additional insights," Chief Medical Officer Sandra Silberman said.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
March 25, 2025 08:49 ET (12:49 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.